Humberto Barbosa da Costa Filho

Humberto Barbosa da Costa Filho

Auto-generated profile, based on publicly available information

Humberto Barbosa da Costa Filho

Federal University of Ceará Fortaleza Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2024 in The Laryngoscope
Verified
Journal Article
Closed access
TSThiago M.A.L. Sales
Thiago M.A.L. Sales
FSFlavio M.N.O. Sidou
Flavio M.N.O. Sidou
HFHumberto B. da Costa Filho
Humberto B. da Costa Filho
KNKerolayne de Melo Nogueira
Kerolayne de Melo Nogueira
GJGenilson J. Dias Júnior
Genilson J. Dias Júnior
MSMarcellus H.L.P. de Souza
Marcellus H.L.P. de Souza

8 March 2022 in The Laryngoscope
Verified
Journal Article
Closed access
TSThiago Meneses Araújo Leite Sales
Thiago Meneses Araújo Leite Sales
RNRenata Rocha Do Nascimento
Renata Rocha Do Nascimento
JNJoão Pedro Do Carmo Neto
João Pedro Do Carmo Neto
HFHumberto Barbosa da Costa Filho
Humberto Barbosa da Costa Filho
SPSuliana Mesquita Paula
Suliana Mesquita Paula
MSMarcellus Henrique Loiola Ponte de Souza
Marcellus Henrique Loiola Ponte de Souza

31 October 2025 in Intestinal Research
Verified
Journal Article
Open access
PDF file
HFHumberto Barbosa da Costa Filho
Humberto Barbosa da Costa Filho
GAGerardo Autran Cavalcante Araújo
Gerardo Autran Cavalcante Araújo
TSThiago Meneses Araújo Leite Sales
Thiago Meneses Araújo Leite Sales
SPSuliana Mesquita Paula
Suliana Mesquita Paula
MCMarco Antonio de Freitas Clementino
Marco Antonio de Freitas Clementino
MSMarcellus Henrique Loiola Ponte Souza
Marcellus Henrique Loiola Ponte Souza
Background/Aims: Inflammatory bowel disease can be triggered by disturbances in intestinal mucosal integrity, leading to bacterial transmigration. The treatment of inflammatory bowel diseases must not only aim to reduce inflammation, but also to reverse the damage to mucosal barrier function. Janus kinase (JAK) inhibitors have been used to treat inflammatory diseases, including ulcerative colitis. However, little is known about the ability of this class of drugs to reverse the loss of mucosal integrity. This study evaluated the effects of tofacitinib, a JAK pathway inhibitor, on inflammation and colonic mucosal integrity in a rat model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis. Methods: Colitis was induced in Wistar rats via rectal administration of TNBS (20 mg+50% ethanol). The control group received only saline. The animals were pretreated with tofacitinib (15 mg/kg) or saline 30 minutes before induction and twice daily thereafter. Seven days after induction, the animals were euthanized, the colon was removed, and myeloperoxidase activity, baseline transepithelial electrical resistance (TER), TER after 1 hour, and fluorescein permeability were assessed. Tight junction proteins in the colon (claudin-2, claudin-15, and tricellulin) were detected using Western blotting. Results: Tofacitinib treatment significantly reduced (P< 0.05) the inflammatory parameters and preserved the integrity of the intestinal epithelial barrier compared with the colitis group (P< 0.05), increased baseline TER, reduced the drop in TER after 1 hour, and decreased paracellular permeability to fluorescein by reducing claudin-2 and claudin-15 expression. Conclusions: JAK inhibition by tofacitinib restored colonic barrier function through antiinflammatory effects and decreased claudin-2 and claudin-15 expressions.

1 January 2023 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
PDF file
HCH.B. Costa-Filho
H.B. Costa-Filho
TST.M.A.L. Sales
T.M.A.L. Sales
SPS.M. Paula
S.M. Paula
LNLucas Antônio Duarte Nicolau
Lucas Antônio Duarte Nicolau
MQM.L. Queiroga
M.L. Queiroga
MSM.H.L.P. Souza
M.H.L.P. Souza
The role of cyclooxygenase (COXs) isoforms in maintaining colonic mucosal integrity is not fully understood. This study aimed to evaluate the role of COX-1 and -2 on colonic mucosal integrity in an experimental colitis model. Colitis was induced in Wistar rats by intracolonic administration of 2,4,6-trinitrobenzenesulfonic acid (20 mg + 50% ethanol). The control group (sham group) received saline only. After 7, 14, or 28 days, colonic samples were removed, and macroscopic lesion scores, wet weight, myeloperoxidase activity, and transepithelial electrical resistance (TER) were determined. In other rat groups, colonic samples from the sham group and a 7th day post-colitis group were mounted in Üssing chambers with the luminal side exposed to a buffer solution (control), acetylsalicylic acid (ASA), SC-560 (COX-1 inhibitor), or celecoxib (COX-2 inhibitor). TER and epithelial permeability to fluorescein were measured. The 7th day colitis group had higher macroscopic damage scores, wet weight, and myeloperoxidase activity and lower basal TER than the sham, 14th day colitis, and 28th day colitis groups. Inhibition of COX-1 but not COX-2 significantly decreased TER and increased permeability to fluorescein in the 7th day post-colitis group compared to the sham group. Additionally, ASA decreased the colonic mucosal integrity on day seven post-colitis compared to the sham group. A decrease in the colonic mucosa integrity in the experimental colitis model can be aggravated only by the inhibition of COX-1, which demonstrated the importance of this enzyme in the maintenance of colonic mucosal integrity.

3 January 2026 in Revista Brasileira de Farmacognosia
Verified
Journal Article
Closed access
VAViviane Pinheiro Alves de Almeida
Viviane Pinheiro Alves de Almeida
TSTino Marcos Lino da Silva
Tino Marcos Lino da Silva
DMDiva de Aguiar Magalhães
Diva de Aguiar Magalhães
ACAna Clara Coelho da Costa
Ana Clara Coelho da Costa
FLFernando Mesquita de Sousa de Lima
Fernando Mesquita de Sousa de Lima
ALAndre Luiz
Andre Luiz